Position
Fidelity in Crispr Therapeutics Ag
Back to the book · All holders of CRSP
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $13.3M$47.57 → $54.54
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 1.95M | $102.5M | — | — | — | 0.0% |
| Q1 2026 | 1.95M | $93M | $47.57 | −$9.52M | $35.1K | 0.0% |
| Q2 2026 | 1.91M | $104.1M | $54.54 | $13.3M | −$2.2M | 0.0% |